| Prev Close | 0.00 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 0.00 / 0.00 |
| Exchange | NASDAQ |
| Market Cap | 1.25B |
| Div & Yield | N.A. (N.A) |
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc.
Levi & Korsinsky is investigating the Board of Directors of Cadence Pharmaceuticals Inc.
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cadence Pharmaceuticals, Inc.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Cadence...
Had you stuck with his stock after Kozlowski was charged in 2002 you might now be richly rewarded.
Kirby McInerney LLP is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc.
Levi & Korsinsky is investigating the Board of Directors of Cadence Pharmaceuticals Inc.
Irish buyer offers a 26% premium to secure Cadence's Ofirmev injectable pain killer, which recently won approval in Canada.
Cadence sells an intravenous form of the painkiller acetaminophen used in hospitals.
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc.
Investors in Cadence Pharmaceuticals Inc saw new options become available this week, for the August 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 229 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
After a weak October, biotech stocks have rebounded in a big way in November. The sector is on pace for an history year of absolute and relative performance.
Investors in Cadence Pharmaceuticals Inc saw new options become available this week, for the January 2014 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CADX options chain for the new January 2014 contracts and identified one put and one call contract of particular interest.
Investors considering a purchase of Cadence Pharmaceuticals Inc shares, but tentative about paying the going market price of $6.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2014 put at the $5 strike, which has a bid at the time of this writing of 35 cents.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
The most recent short interest data has been released by the NASDAQ for the 08/15/2013 settlement date, which shows a 781,695 share decrease in total short interest for Cadence Pharmaceuticals Inc , to 2,361,133, a decrease of 24.87% since 07/31/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
In trading on Wednesday, shares of Cadence Pharmaceuticals Inc crossed below their 200 day moving average of $5.77, changing hands as low as $5.71 per share. Cadence Pharmaceuticals Inc shares are currently trading down about 4.2% on the day.
The most recent short interest data has been released by the NASDAQ for the 07/31/2013 settlement date, which shows a 356,691 share decrease in total short interest for Cadence Pharmaceuticals Inc , to 3,142,828, a decrease of 10.19% since 07/15/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
These stocks look ready to break out and trade higher from current levels.
These under-$10 stocks look poised to trade higher from current levels.
Portfolio manager David Peltier analyzes a volatile, low-dollar drug stock.
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Cadence Pharmaceuticals' Management Presents at the 2012 Wedbush PACGROW Life Sciences Management Access Conference (Transcript)
